Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Brain Neoplasms 24Melanoma 19Glioblastoma 13Neuroblastoma 6Glioma 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Wilms Tumor 2Seminoma 2Rhabdomyosarcoma 2Osteosarcoma 2Neoplasm Metastasis 2Meningioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hodgkin Disease 2Gliosarcoma 2Central Nervous System Neoplasms 2Astrocytoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1

Interventions

regorafenib 2Nivolumab 2pembrolizumab 1aflibercept 1adavosertib 1Radiotherapy 1Radiation 1Paclitaxel 1NEO212 1Ipilimumab 1IFL protocol 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Ipilimumab × CNS × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡